Loading...

OPKO Health

DB:XCY
Snowflake Description

Adequate balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XCY
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • OPKO Health has significant price volatility in the past 3 months.
XCY Share Price and Events
7 Day Returns
-19.2%
DB:XCY
-0.6%
DE Biotechs
0.4%
DE Market
1 Year Returns
-33.7%
DB:XCY
-8.2%
DE Biotechs
-17.5%
DE Market
XCY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OPKO Health (XCY) -19.2% -19.2% -21.2% -33.7% -68.6% -56.3%
DE Biotechs -0.6% 3.4% -11.7% -8.2% 33.6% -3.3%
DE Market 0.4% -3.8% -10.6% -17.5% -3.5% 4.4%
1 Year Return vs Industry and Market
  • XCY underperformed the Biotechs industry which returned -8.2% over the past year.
  • XCY underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
XCY
Industry
5yr Volatility vs Market

Value

 Is OPKO Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of OPKO Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for OPKO Health.

DB:XCY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:XCY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.86
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.857 (1 + (1- 21%) (11.33%))
0.934
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.934 * 9.46%)
9.37%

Discounted Cash Flow Calculation for DB:XCY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for OPKO Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:XCY DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -50.57 60.65 236.00 387.30 449.27
Source Analyst x3 Analyst x2 Analyst x1 Analyst x1 Est @ 16%, capped from 43.98%
Present Value
Discounted (@ 9.37%)
-46.23 50.70 180.38 270.65 287.05
Present value of next 5 years cash flows $742.54
DB:XCY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $449.27 × (1 + 0.54%) ÷ (9.37% – 0.54%)
$5,114.90
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $5,114.90 ÷ (1 + 9.37%)5
$3,268.02
DB:XCY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $742.54 + $3,268.02
$4,010.56
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,010.56 / 559.83
$6.23
DB:XCY Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:XCY represents 0.8693x of NasdaqGS:OPK
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8693x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 7.16 x 0.8693
€6.23
Value per share (EUR) From above. €6.23
Current discount Discount to share price of €2.86
= -1 x (€2.86 - €6.23) / €6.23
54.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price OPKO Health is available for.
Intrinsic value
>50%
Share price is €2.86 vs Future cash flow value of €6.23
Current Discount Checks
For OPKO Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • OPKO Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • OPKO Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OPKO Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OPKO Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XCY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.53
NasdaqGS:OPK Share Price ** NasdaqGS (2018-12-17) in USD $3.29
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 25.93x
Germany Market PE Ratio Median Figure of 418 Publicly-Listed Companies 16.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OPKO Health.

DB:XCY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OPK Share Price ÷ EPS (both in USD)

= 3.29 ÷ -0.53

-6.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OPKO Health is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OPKO Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OPKO Health's expected growth come at a high price?
Raw Data
DB:XCY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
53.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.04x
Germany Market PEG Ratio Median Figure of 279 Publicly-Listed Companies 1.3x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OPKO Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OPKO Health's assets?
Raw Data
DB:XCY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $3.19
NasdaqGS:OPK Share Price * NasdaqGS (2018-12-17) in USD $3.29
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.48x
Germany Market PB Ratio Median Figure of 567 Publicly-Listed Companies 1.73x
DB:XCY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OPK Share Price ÷ Book Value per Share (both in USD)

= 3.29 ÷ 3.19

1.03x

* Primary Listing of OPKO Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OPKO Health is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OPKO Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OPKO Health has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OPKO Health expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OPKO Health expected to grow at an attractive rate?
  • OPKO Health's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • OPKO Health's earnings growth is expected to exceed the Germany market average.
  • OPKO Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:XCY Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XCY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 53.1%
DB:XCY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 10.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 16.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XCY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XCY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,587 185 130 2
2021-12-31 1,331 125 37 2
2020-12-31 1,169 72 -72 5
2019-12-31 1,077 -6 -133 5
2018-12-31 1,015 -82 -130 4
DB:XCY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 1,031 -72 -299
2018-06-30 1,027 -88 -307
2018-03-31 1,056 -94 -317
2017-12-31 1,068 -92 -309
2017-09-30 1,081 -64 -101
2017-06-30 1,133 -58 -80
2017-03-31 1,197 7 -48
2016-12-31 1,222 32 -25
2016-09-30 1,222 -8 -10
2016-06-30 1,067 -7 133
2016-03-31 753 -84 75
2015-12-31 492 164 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OPKO Health's earnings are expected to grow significantly at over 20% yearly.
  • OPKO Health's revenue is expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XCY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from OPKO Health Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XCY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.21 0.31 0.11 2.00
2021-12-31 0.06 0.11 0.01 2.00
2020-12-31 -0.12 -0.01 -0.35 5.00
2019-12-31 -0.23 -0.09 -0.35 5.00
2018-12-31 -0.23 -0.20 -0.25 4.00
DB:XCY Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.53
2018-06-30 -0.55
2018-03-31 -0.57
2017-12-31 -0.55
2017-09-30 -0.18
2017-06-30 -0.14
2017-03-31 -0.09
2016-12-31 -0.05
2016-09-30 -0.02
2016-06-30 0.25
2016-03-31 0.15
2015-12-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OPKO Health will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess OPKO Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OPKO Health has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OPKO Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OPKO Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OPKO Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OPKO Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OPKO Health's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OPKO Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OPKO Health Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XCY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 1,030.89 -298.50 478.64 30.83
2018-06-30 1,027.12 -306.77 497.74 38.27
2018-03-31 1,056.04 -317.48 515.67 36.79
2017-12-31 1,067.50 -308.87 534.09 35.75
2017-09-30 1,080.51 -101.00 458.03 43.15
2017-06-30 1,132.50 -80.06 479.00 39.98
2017-03-31 1,197.01 -47.61 490.93 40.15
2016-12-31 1,221.66 -25.08 491.79 40.63
2016-09-30 1,222.36 -9.82 463.21 42.12
2016-06-30 1,067.36 133.40 394.31 41.53
2016-03-31 752.69 75.11 297.73 44.19
2015-12-31 491.74 -30.03 204.38 43.72
2015-09-30 241.08 -84.60 111.47 52.61
2015-06-30 117.82 -261.52 70.24 49.46
2015-03-31 98.94 -244.23 64.17 43.32
2014-12-31 91.13 -171.67 60.54 41.02
2014-09-30 86.28 -135.50 60.04 41.81
2014-06-30 87.15 -146.82 59.60 39.40
2014-03-31 87.43 -124.74 58.61 36.10
2013-12-31 96.53 -114.83 57.22 34.31
2013-09-30 92.10 -99.06 50.24 31.19
2013-06-30 83.25 -49.45 43.99 27.44
2013-03-31 69.64 -56.86 35.55 24.47
2012-12-31 47.04 -31.29 29.10 18.51
2012-09-30 36.58 -20.50 22.50 17.20
2012-06-30 31.59 -17.46 19.52 16.88
2012-03-31 29.81 -12.62 18.79 15.10
2011-12-31 27.98 -8.84 19.17 11.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OPKO Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OPKO Health has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OPKO Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OPKO Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OPKO Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OPKO Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OPKO Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OPKO Health's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • OPKO Health's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of OPKO Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OPKO Health Company Filings, last reported 2 months ago.

DB:XCY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 1,788.64 208.75 43.72
2018-06-30 1,810.50 209.75 80.38
2018-03-31 1,823.26 209.15 99.94
2017-12-31 1,885.38 157.99 91.50
2017-09-30 2,089.04 151.09 100.36
2017-06-30 2,106.83 132.47 130.53
2017-03-31 2,106.97 103.33 131.05
2016-12-31 2,091.81 105.45 168.73
2016-09-30 2,105.39 112.70 144.65
2016-06-30 2,015.64 109.07 171.65
2016-03-31 1,997.87 149.92 174.97
2015-12-31 1,979.79 149.74 193.60
2015-09-30 1,969.37 145.35 212.14
2015-06-30 826.99 125.95 221.22
2015-03-31 812.57 122.46 348.19
2014-12-31 835.74 147.34 96.91
2014-09-30 887.34 129.96 118.26
2014-06-30 912.83 133.71 134.01
2014-03-31 831.25 238.93 156.40
2013-12-31 872.98 227.74 185.80
2013-09-30 867.93 226.74 180.84
2013-06-30 312.48 208.94 169.09
2013-03-31 319.78 220.39 181.60
2012-12-31 203.28 22.68 27.36
2012-09-30 170.65 21.36 42.35
2012-06-30 175.89 14.57 55.29
2012-03-31 179.37 14.19 62.12
2011-12-31 185.27 8.76 71.52
  • OPKO Health's level of debt (11.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (26.1% vs 11.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making OPKO Health has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making OPKO Health has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -100% per year.
X
Financial health checks
We assess OPKO Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OPKO Health has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OPKO Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OPKO Health dividends.
If you bought €2,000 of OPKO Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OPKO Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OPKO Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XCY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XCY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OPKO Health has not reported any payouts.
  • Unable to verify if OPKO Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OPKO Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OPKO Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OPKO Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OPKO Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OPKO Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OPKO Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Phil Frost
COMPENSATION $970,800
AGE 82
TENURE AS CEO 11.8 years
CEO Bio

Dr. Phillip Frost, also known as Phil, M.D., Ph.D., has been Chief Executive Officer of Opko Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and General Partner of Frost Phillip MD Et Al. He serves as General Partner at Frost Group, LLC, Frost Group LLC and Incentive 2 Management Inc. (Alternate Name: Incentive Management Inc.). He also serves as Chief Executive Officer of Opko Health Inc. at Claros Diagnostics, Inc. He is also employed at MBF Healthcare Partners, L.P. He served as a Special Advisor of Castle Brands Inc. He served as a General Partner of Peregrine Ventures. He served as the Chief Executive Officer of eXegenics Inc. He served as the Chief Executive Officer of IVAX Corporation. He served as Chief Executive Officer from 1987 to January 26, 2006 and also served as its President from July 1991 to January 1995 at IVAX LLC. He served as Lieutenant Commander in the U.S. Public Health Service at the National Cancer Institute, in Bethesda, Maryland from 1963 to 1965. He served as Chief Executive Officer at Teva Pharmaceutical Industries in 1987. He has been the Chairman of Opko Health, Inc. since March 27, 2007. He has been the Chairman of OPKO Biologics since March 2008. He serves as the Chairman of the Board of Non-Invasive Monitoring Systems Inc. He serves as the Chairman of Temple Emanu El. He serves as the Chairman of Medical Advisory Board of Daxor Corporation. He has been the Chairman of Strategic Advisory Board and Member of Strategic Advisory Board at Drone Aviation Holding Corp. since August 28, 2014. He serves as the Chairman of University of Miami. Dr. Frost is a Co-Owner at Frost Gamma Investments Trust. He serves as Vice Chairman at IDI, Inc. He has been a Director of Cocrystal Pharma, Inc. since January 2, 2014 and OPKO Biologics since May 2007. He serves as a Director at Non-Invasive Monitoring Systems Inc. He has been a Senior Trustee of University of Miami since 1983. He serves as a Member of Advisory Board at Non-Invasive Monitoring Systems Inc. He serves as a Director of Fabrus, Inc. and The Center for Blood Research Inc., an affiliate of the Harvard Medical School. He has been a Director of IDI, Inc. since December 8, 2015, Opko Health, Inc. since March 27, 2007 and Independent Director of Sevion Therapeutics, Inc. (formerly Senesco Technologies, Inc.) since May 2014. He serves as a Governor of Tel Aviv University. He also serves as a Member of the Florida Council of 100. He serves as a Trustee of each of the Scripps Research Institutes, the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He was a Director of Ladenburg Thalmann Financial Services Inc., since March 2004. He served as Chairman at Ladenburg Thalmann Financial Services Inc. since July 2006 until September 21, 2018. He serves as Chairman and Director at Claros Diagnostics, Inc. He served as the Chairman and Director of Ideation Acquisition Corp. from June 1, 2007 to October 30, 2009, ERBA Diagnostics, Inc. from March 2001 to April 2006, IVAX Corporation since 1987 and Key Pharmaceutical Inc., from 1972 to 1986. He served as the Chairman and Director of Whitman Education Group, Inc. from 1992 to 2003. Dr. Frost served as the Chairman of Key Pharmaceuticals, Inc. from 1972 to 1986. He served as the Chairman and Director of IVAX Diagnostics Inc. He served as the Chairman of Teva Pharmaceutical Industries Limited from March 2010 to December 31, 2014. He served as an Executive Vice Chairman and Director at Tiger Media, Inc. since December 9, 2015. He served as Vice Chairman of Teva Pharmaceutical Industries Limited from January 2006 to March 2010. He served as a Co-Vice Chairman of NYSE MKT LLC since April 2005 and served as its Governor. He served as a Co-Vice Chairman of American Stock Exchange LLC from April 2005 to 2008 and its Governor from 1992 to 2008. He served as the Chairman of the Board of Continucare Corporation from September 1996 to April 2002, Pan Am Corporation since April 16, 1996 and North American Vaccine from December 1990 to 2000. He served as a Director from May 2001 to July 2002 at Ladenburg Thalmann Financial Services Inc. He served as Director from September 2005 to September 12, 2007 at Castle Brands Inc. He served as a Member of Scientific Advisory Board at MusclePharm Corporation. He served as an Independent Director of Continucare Corporation since January 2004. He served as a Director of PROLOR Biotech, Inc. since May 2007. He served as a Director of North American Vaccine since October 1989, ERBA Diagnostics, Inc., from 2001 to April 2006, Orthodontix Inc., since January 03, 2007, Cellular Technical Services Co. Inc. since April 12, 2005 and Protalix BioTherapeutics, Inc., from December 31, 2006 to December 2007. He served as a Director of Teva Pharmaceutical Industries Limited from 2006 to February 4, 2015. He served as a Director of American Exploration Company from 1983 to 1998 and Northrup Grumman Corporation from 1996 to May 20, 2009. He served as a Director of TransEnterix, Inc. since 2013. He served as a Member of Board of Regents of Smithsonian Institution from 2006 to 2010. He served as a Director of Teva Czech Industries s.r.o. He served as a Director of SafeStitch Medical, Inc., since 2005. He served as a Director of Northrop Grumman Corporation from 1996 to May 20, 2009, Pan Am Corporation since March 8, 1996 and IVAX LLC since 1987. He served as a Director of GBI Capital Management Corp., IVAX-CR AS and IVAX Pharmaceuticals s.r.o. He served as a Director of CoCrystal Discovery, Inc. He served as the Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1990. He served as the Chairman of the Board at IVAX LLC from 1987 to January 26, 2006. He served as the Vice Chairman of Cogint, Inc. from December 2015 to March 12, 2018 and as its Director from December 8, 2015 until March 12, 2018. His internship was conducted at the University of Chicago Hospitals and Clinics in Straight Medicine. He attended the University of Paris from 1995 to 1996. Dr. Frost received a B.A. in French Literature from the University of Pennsylvania in 1957 and Doctor of Medicine Degree from the Albert Einstein College of Medicine, New York in 1961.

CEO Compensation
  • Phil's compensation has been consistent with company performance over the past year.
  • Phil's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OPKO Health management team in years:

4.8
Average Tenure
59
Average Age
  • The tenure for the OPKO Health management team is about average.
Management Team

Phil Frost

TITLE
Chairman & CEO
COMPENSATION
$971K
AGE
82
TENURE
11.8 yrs

Jane Hsiao

TITLE
Vice Chairman & CTO
COMPENSATION
$916K
AGE
71
TENURE
11.6 yrs

Adam Logal

TITLE
Senior VP & CFO
COMPENSATION
$611K
AGE
40
TENURE
4.8 yrs

Steve Rubin

TITLE
Executive VP of Administration & Director
COMPENSATION
$821K
AGE
58
TENURE
11.6 yrs

Kate Inman

TITLE
General Counsel & Secretary
AGE
45

James DeMarco

TITLE
Senior Vice President of Pharmaceutical Sales
TENURE
2.7 yrs

Tom Nusbickel

TITLE
Chief Commercial Officer
TENURE
2.6 yrs

Akhtar Ashfaq

TITLE
Senior Vice President of Clinical Research & Development and Medical Affairs
TENURE
1.8 yrs

David Okrongly

TITLE
President of OPKO Diagnostics
AGE
59
TENURE
5.4 yrs

Arie Gutman

TITLE
Chief Executive Officer of Active Pharmaceutical Ingredient and Chemical Development Division
AGE
64
TENURE
4.7 yrs
Board of Directors Tenure

Average tenure and age of the OPKO Health board of directors in years:

11.8
Average Tenure
72.5
Average Age
  • The average tenure for the OPKO Health board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Phil Frost

TITLE
Chairman & CEO
COMPENSATION
$971K
AGE
82
TENURE
11.8 yrs

Jane Hsiao

TITLE
Vice Chairman & CTO
COMPENSATION
$916K
AGE
71
TENURE
11.6 yrs

Steve Rubin

TITLE
Executive VP of Administration & Director
COMPENSATION
$821K
AGE
58
TENURE
11.8 yrs

Richard Lerner

TITLE
Independent Director & Member of Scientific Advisory Board
COMPENSATION
$80K
AGE
80
TENURE
11.8 yrs

Rick Pfenniger

TITLE
Independent Director
COMPENSATION
$110K
AGE
63
TENURE
10.9 yrs

John Paganelli

TITLE
Independent Director
COMPENSATION
$84K
AGE
83
TENURE
15 yrs

Alice Yu

TITLE
Independent Director
COMPENSATION
$70K
AGE
74
TENURE
9.7 yrs

Roger Kornberg

TITLE
Member of Scientific Advisory Board
AGE
71

Thomas Kodadek

TITLE
Member of Scientific Advisory Board

Tahir Ahmed

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Sep 18 Buy Phillip Frost Individual 07. Sep 18 07. Sep 18 10,000 €4.89 €48,107
10. Sep 18 Buy Robert Fishel Individual 07. Sep 18 07. Sep 18 10,000 €4.00 €39,985
06. Sep 18 Buy Phillip Frost Individual 05. Sep 18 05. Sep 18 10,000 €5.00 €49,895
31. Aug 18 Buy Phillip Frost Individual 30. Aug 18 30. Aug 18 5,000 €5.06 €25,307
29. Aug 18 Buy Phillip Frost Individual 28. Aug 18 28. Aug 18 5,000 €4.95 €24,746
27. Aug 18 Buy Phillip Frost Individual 24. Aug 18 24. Aug 18 15,000 €4.95 €73,619
20. Aug 18 Buy Phillip Frost Individual 17. Aug 18 17. Aug 18 10,000 €4.90 €48,505
14. Aug 18 Buy Phillip Frost Individual 13. Aug 18 13. Aug 18 15,000 €4.74 €70,036
10. Aug 18 Buy Phillip Frost Individual 09. Aug 18 09. Aug 18 10,000 €4.73 €47,120
27. Jul 18 Buy Phillip Frost Individual 26. Jul 18 26. Jul 18 90,000 €4.40 €390,293
26. Jul 18 Buy Phillip Frost Individual 25. Jul 18 25. Jul 18 60,000 €4.72 €281,210
25. Jul 18 Buy Phillip Frost Individual 24. Jul 18 24. Jul 18 55,000 €4.95 €263,204
23. Jul 18 Buy Phillip Frost Individual 20. Jul 18 20. Jul 18 10,000 €5.03 €50,306
20. Jul 18 Buy Phillip Frost Individual 19. Jul 18 19. Jul 18 10,000 €5.13 €51,289
19. Jul 18 Buy Phillip Frost Individual 18. Jul 18 18. Jul 18 10,000 €5.20 €51,963
17. Jul 18 Buy Phillip Frost Individual 16. Jul 18 16. Jul 18 15,000 €4.89 €72,811
12. Jul 18 Buy Robert Fishel Individual 11. Jul 18 11. Jul 18 2,500 €5.12 €12,795
05. Jul 18 Buy Phillip Frost Individual 03. Jul 18 03. Jul 18 10,000 €4.10 €40,746
02. Jul 18 Buy Phillip Frost Individual 29. Jun 18 29. Jun 18 7,720 €4.05 €31,143
29. Jun 18 Buy Phillip Frost Individual 28. Jun 18 28. Jun 18 20,000 €4.10 €80,767
28. Jun 18 Buy Phillip Frost Individual 27. Jun 18 27. Jun 18 10,000 €4.10 €40,974
25. Jun 18 Buy Phillip Frost Individual 22. Jun 18 22. Jun 18 10,000 €3.82 €38,248
20. Jun 18 Buy Phillip Frost Individual 19. Jun 18 19. Jun 18 20,000 €3.76 €74,546
19. Jun 18 Buy Phillip Frost Individual 18. Jun 18 18. Jun 18 14,299 €3.74 €53,387
18. Jun 18 Buy Phillip Frost Individual 15. Jun 18 15. Jun 18 10,000 €3.80 €38,030
12. Jun 18 Buy Phillip Frost Individual 11. Jun 18 11. Jun 18 10,000 €3.57 €35,739
08. Jun 18 Buy Phillip Frost Individual 07. Jun 18 07. Jun 18 10,000 €3.42 €34,166
07. Jun 18 Buy Phillip Frost Individual 06. Jun 18 06. Jun 18 30,000 €3.47 €103,251
01. Jun 18 Buy Phillip Frost Individual 31. May 18 31. May 18 3,900 €3.22 €12,577
30. May 18 Buy Robert Fishel Individual 29. May 18 29. May 18 2,500 €3.23 €8,077
29. May 18 Buy Phillip Frost Individual 25. May 18 25. May 18 10,000 €3.17 €31,742
24. May 18 Buy Phillip Frost Individual 23. May 18 23. May 18 40,000 €3.25 €127,577
23. May 18 Buy Phillip Frost Individual 22. May 18 22. May 18 10,000 €3.17 €31,660
22. May 18 Buy Phillip Frost Individual 21. May 18 21. May 18 90,000 €3.38 €292,619
21. May 18 Buy Phillip Frost Individual 18. May 18 18. May 18 100,000 €3.69 €343,099
15. May 18 Buy Robert Fishel Individual 14. May 18 14. May 18 1,800 €4.00 €7,204
07. May 18 Buy Robert Fishel Individual 04. May 18 04. May 18 5,000 €2.63 €13,161
26. Apr 18 Buy Robert Fishel Individual 25. Apr 18 25. Apr 18 12,500 €2.49 €30,468
17. Apr 18 Buy Robert Fishel Individual 16. Apr 18 16. Apr 18 15,000 €2.43 €36,463
16. Apr 18 Buy Robert Fishel Individual 13. Apr 18 13. Apr 18 10,000 €2.45 €24,504
09. Apr 18 Buy Robert Fishel Individual 06. Apr 18 06. Apr 18 10,000 €2.57 €25,741
07. May 18 Buy Phillip Frost Individual 04. May 18 04. May 18 26,000 €2.63 €68,355
04. May 18 Buy Phillip Frost Individual 03. May 18 03. May 18 51,800 €2.60 €133,822
03. May 18 Buy Phillip Frost Individual 02. May 18 02. May 18 50,330 €2.66 €132,503
02. May 18 Buy Phillip Frost Individual 01. May 18 01. May 18 31,222 €2.58 €79,339
01. May 18 Buy Phillip Frost Individual 30. Apr 18 30. Apr 18 7,600 €2.60 €19,743
01. May 18 Buy Phillip Frost Individual 30. Apr 18 30. Apr 18 67,400 €2.58 €171,676
27. Apr 18 Buy Phillip Frost Individual 26. Apr 18 26. Apr 18 31,800 €2.52 €79,677
26. Apr 18 Buy Phillip Frost Individual 25. Apr 18 25. Apr 18 55,372 €2.49 €135,696
25. Apr 18 Buy Phillip Frost Individual 24. Apr 18 24. Apr 18 75,000 €2.45 €182,187
24. Apr 18 Buy Phillip Frost Individual 23. Apr 18 23. Apr 18 75,000 €2.52 €186,336
23. Apr 18 Buy Phillip Frost Individual 20. Apr 18 20. Apr 18 60,000 €2.56 €152,748
20. Apr 18 Buy Phillip Frost Individual 19. Apr 18 19. Apr 18 10,000 €2.57 €25,661
17. Apr 18 Buy Phillip Frost Individual 16. Apr 18 16. Apr 18 50,000 €2.45 €122,043
16. Apr 18 Buy Phillip Frost Individual 13. Apr 18 13. Apr 18 30,000 €2.43 €72,864
13. Apr 18 Buy Phillip Frost Individual 12. Apr 18 12. Apr 18 65,000 €2.50 €160,188
12. Apr 18 Buy Phillip Frost Individual 11. Apr 18 11. Apr 18 43,000 €2.50 €106,383
11. Apr 18 Buy Phillip Frost Individual 10. Apr 18 10. Apr 18 36,527 €2.50 €90,593
10. Apr 18 Buy Phillip Frost Individual 09. Apr 18 09. Apr 18 80,000 €2.52 €197,266
09. Apr 18 Buy Phillip Frost Individual 06. Apr 18 06. Apr 18 60,000 €2.56 €151,639
06. Apr 18 Buy Phillip Frost Individual 05. Apr 18 05. Apr 18 10,000 €2.66 €26,585
04. Apr 18 Buy Phillip Frost Individual 03. Apr 18 03. Apr 18 153,000 €2.48 €373,914
29. Mar 18 Buy Phillip Frost Individual 28. Mar 18 28. Mar 18 80,000 €2.53 €199,128
28. Mar 18 Buy Phillip Frost Individual 27. Mar 18 27. Mar 18 86,100 €2.67 €225,541
27. Mar 18 Buy Phillip Frost Individual 26. Mar 18 26. Mar 18 26,000 €2.61 €66,743
26. Mar 18 Buy Phillip Frost Individual 23. Mar 18 23. Mar 18 25,000 €2.65 €66,128
23. Mar 18 Buy Phillip Frost Individual 22. Mar 18 22. Mar 18 30,000 €2.75 €80,788
22. Mar 18 Buy Phillip Frost Individual 21. Mar 18 21. Mar 18 30,000 €2.76 €82,678
21. Mar 18 Buy Phillip Frost Individual 20. Mar 18 20. Mar 18 75,000 €2.81 €203,432
20. Mar 18 Buy Phillip Frost Individual 19. Mar 18 19. Mar 18 40,000 €2.87 €113,791
16. Mar 18 Buy Phillip Frost Individual 15. Mar 18 15. Mar 18 61,000 €2.74 €164,389
14. Mar 18 Buy Phillip Frost Individual 13. Mar 18 13. Mar 18 67,500 €2.76 €183,194
14. Mar 18 Buy Adam Logal Individual 13. Mar 18 13. Mar 18 2,065 €2.74 €5,658
13. Mar 18 Buy Phillip Frost Individual 12. Mar 18 12. Mar 18 25,000 €2.87 €70,649
09. Mar 18 Buy Phillip Frost Individual 08. Mar 18 08. Mar 18 32,000 €2.71 €85,011
08. Mar 18 Buy Phillip Frost Individual 07. Mar 18 07. Mar 18 75,000 €2.72 €199,335
08. Mar 18 Buy Steven Rubin Individual 07. Mar 18 07. Mar 18 6,000 €2.62 €15,740
05. Mar 18 Buy Phillip Frost Individual 02. Mar 18 02. Mar 18 364,800 €2.39 €871,965
22. Feb 18 Buy Phillip Frost Individual 21. Feb 18 21. Feb 18 172,500 €3.00 €508,714
12. Feb 18 Buy Phillip Frost Individual 09. Feb 18 09. Feb 18 185,000 €3.13 €578,745
09. Feb 18 Buy Phillip Frost Individual 08. Feb 18 08. Feb 18 20,000 €3.31 €66,039
08. Feb 18 Buy Phillip Frost Individual 07. Feb 18 07. Feb 18 78,000 €3.52 €267,977
07. Feb 18 Buy Phillip Frost Individual 06. Feb 18 06. Feb 18 60,000 €3.51 €204,604
06. Feb 18 Buy Phillip Frost Individual 05. Feb 18 05. Feb 18 50,000 €3.36 €166,606
05. Feb 18 Buy Phillip Frost Individual 02. Feb 18 02. Feb 18 55,000 €3.49 €190,243
01. Feb 18 Buy Phillip Frost Individual 31. Jan 18 31. Jan 18 65,000 €3.62 €233,465
29. Jan 18 Buy Phillip Frost Individual 26. Jan 18 26. Jan 18 55,000 €4.04 €217,064
26. Jan 18 Buy Phillip Frost Individual 25. Jan 18 25. Jan 18 75,000 €4.01 €299,214
25. Jan 18 Buy Phillip Frost Individual 24. Jan 18 24. Jan 18 100,000 €4.02 €394,338
24. Jan 18 Buy Phillip Frost Individual 23. Jan 18 23. Jan 18 100,000 €3.88 €387,664
23. Jan 18 Buy Phillip Frost Individual 22. Jan 18 22. Jan 18 100,000 €3.62 €358,818
X
Management checks
We assess OPKO Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OPKO Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Details
Name: OPKO Health, Inc.
XCY
Exchange: DB
Founded: 1991
$1,623,575,370
559,827,515
Website: http://www.opko.com
Address: OPKO Health, Inc.
4400 Biscayne Boulevard,
Miami,
Florida, 33137,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OPK Common Stock Nasdaq Global Select US USD 02. Nov 1995
DB XCY Common Stock Deutsche Boerse AG DE EUR 02. Nov 1995
LSE 0KCS Common Stock London Stock Exchange GB USD 02. Nov 1995
TASE OPK Common Stock The Tel-Aviv Stock Exchange IL ILS 02. Nov 1995
BMV OPK * Common Stock Bolsa Mexicana de Valores MX MXN 02. Nov 1995
Number of employees
Current staff
Staff numbers
6,030
OPKO Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/17 21:34
End of day share price update: 2018/12/17 00:00
Last estimates confirmation: 2018/12/06
Last earnings filing: 2018/11/09
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.